



## Fiscal Estimate Narratives

ETF 9/24/2013

LRB Number	<b>13-0647/1</b>	Introduction Number	<b>SB-300</b>	Estimate Type	<b>Original</b>
<b>Description</b> Copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy					

### Assumptions Used in Arriving at Fiscal Estimate

This bill prohibits health insurance plans providing coverage to state and participating local government participants from charging those participants a higher deductible, co-insurance or co-payment for oral chemotherapy than they are charged for receiving intra-venous or injected chemotherapy (IIC). Under benefits currently available to these participants, this bill will have fiscal effect by eliminating the applicable co-payments for out-patient prescription drugs.

Based on 2013 costs and benefits, the cost to the state is under \$35,692 annually (\$0.02 per member per month x 12 months x 169,000 members x .88 state share of premium).

For the Wisconsin Public Employers (local government) health plan the cost is under \$7,000 annually.

This estimate assumes that a general increase in deductibles or co-insurance is allowable under the law since it would not single out chemotherapy benefits for cost increases. Thus while the law provides that a plan cannot increase the cost of IIC in order to comply, an increase in cost-sharing generally under the plan would be allowable even if it resulted in increased costs for chemotherapy if that cost increase also applied to other benefits under the plan.

Finally this estimate assumes that the following language in the bill: "... may not require a higher co-payment, deductible, or co-insurance amount for oral chemotherapy than it requires for injected or intravenous chemotherapy, regardless of the formulation or benefit category determination by the policy or plan" does not prohibit prior authorization for oral chemotherapy agents or their injected/intravenous equivalents.

The cost of this bill does not include oral chemotherapy agents that are under investigation but are not yet approved the federal Food and Drug Administration.

### Long-Range Fiscal Implications